Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Ever since Medicare proposed to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm, the agency ...
Read moreEver since Medicare proposed to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm, the agency ...
Read moreThe F.D.A. also required Biogen to conduct another clinical trial to determine if the drug provided ...
Read moreBy Kosaku Narioka Eisai Co. shares fell as much as 9.2% early Thursday morning after a ...
Read more© 2022 TheDailyStock.News